- Home
- SCLX vs KLRS Comparison
SCLX vs KLRS Comparison
Compare SCLX & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- KLRS
- Stock Information
- Founded
- SCLX 2011
- KLRS 2019
- Country
- SCLX United States
- KLRS United States
- Employees
- SCLX N/A
- KLRS N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCLX Health Care
- KLRS Health Care
- Exchange
- SCLX Nasdaq
- KLRS Nasdaq
- Market Cap
- SCLX 51.3M
- KLRS 57.5M
- IPO Year
- SCLX N/A
- KLRS N/A
- Fundamental
- Price
- SCLX $4.06
- KLRS $7.01
- Analyst Decision
- SCLX Strong Buy
- KLRS Buy
- Analyst Count
- SCLX 4
- KLRS 1
- Target Price
- SCLX $396.67
- KLRS N/A
- AVG Volume (30 Days)
- SCLX 103.2K
- KLRS 51.2K
- Earning Date
- SCLX 05-12-2025
- KLRS 05-15-2025
- Dividend Yield
- SCLX N/A
- KLRS N/A
- EPS Growth
- SCLX N/A
- KLRS N/A
- EPS
- SCLX N/A
- KLRS N/A
- Revenue
- SCLX $56,590,000.00
- KLRS N/A
- Revenue This Year
- SCLX $115.30
- KLRS N/A
- Revenue Next Year
- SCLX $73.33
- KLRS N/A
- P/E Ratio
- SCLX N/A
- KLRS N/A
- Revenue Growth
- SCLX 21.07
- KLRS N/A
- 52 Week Low
- SCLX $5.80
- KLRS $5.87
- 52 Week High
- SCLX $80.50
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- SCLX 24.27
- KLRS N/A
- Support Level
- SCLX $3.60
- KLRS N/A
- Resistance Level
- SCLX $7.64
- KLRS N/A
- Average True Range (ATR)
- SCLX 1.21
- KLRS 0.00
- MACD
- SCLX -0.37
- KLRS 0.00
- Stochastic Oscillator
- SCLX 6.67
- KLRS 0.00
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.